I built this matrix by mapping each row to the single trial endpoint that produced the highest-quality primary evidence as of mid-2026: percent body-weight change for efficacy (Jastreboff 2023, SURMOUNT-1, STEP 1), three-point MACE for cardiovascular (SELECT), MRI-PDFF for hepatic fat (retatrutide Phase 2 sub-analyses, [unverified primary source]), and treatment-emergent adverse event rates for GI burden
How long can it be at room temperature
The Section 8 IP map reads differently once this dynamic is priced in: the players whose patent estates are anchored to duals rather than triples are holding an asset class that just had its efficacy narrative compressed by six to eight percentage points
Y., Yazici, D., Pizzagalli, D
2024;31(4):e523e527
Over time, these drugs have shown benefits far beyond glycemic control